Historical Valuation
Bolt Biotherapeutics Inc (BOLT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.18 is considered Fairly compared with the five-year average of -1.57. The fair price of Bolt Biotherapeutics Inc (BOLT) is between 2.75 to 9.00 according to relative valuation methord.
Relative Value
Fair Zone
2.75-9.00
Current Price：5.54
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bolt Biotherapeutics Inc (BOLT) has a current Price-to-Book (P/B) ratio of 0.35. Compared to its 3-year average P/B ratio of 0.32 , the current P/B ratio is approximately 9.55% higher. Relative to its 5-year average P/B ratio of 0.54, the current P/B ratio is about -35.39% higher. Bolt Biotherapeutics Inc (BOLT) has a Forward Free Cash Flow (FCF) yield of approximately -424.67%. Compared to its 3-year average FCF yield of -268.54%, the current FCF yield is approximately 58.14% lower. Relative to its 5-year average FCF yield of -185.90% , the current FCF yield is about 128.44% lower.
P/B
Median3y
0.32
Median5y
0.54
FCF Yield
Median3y
-268.54
Median5y
-185.90
Competitors Valuation Multiple
AI Analysis for BOLT
The average P/S ratio for BOLT competitors is 0.89, providing a benchmark for relative valuation. Bolt Biotherapeutics Inc Corp (BOLT.O) exhibits a P/S ratio of 4.18, which is 368.5% above the industry average. Given its robust revenue growth of 90.10%, this premium appears sustainable.
Performance Decomposition
AI Analysis for BOLT
1Y
3Y
5Y
Market capitalization of BOLT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BOLT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BOLT currently overvalued or undervalued?
Bolt Biotherapeutics Inc (BOLT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.18 is considered Fairly compared with the five-year average of -1.57. The fair price of Bolt Biotherapeutics Inc (BOLT) is between 2.75 to 9.00 according to relative valuation methord.
What is Bolt Biotherapeutics Inc (BOLT) fair value?
BOLT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bolt Biotherapeutics Inc (BOLT) is between 2.75 to 9.00 according to relative valuation methord.
How does BOLT's valuation metrics compare to the industry average?
The average P/S ratio for BOLT's competitors is 0.89, providing a benchmark for relative valuation. Bolt Biotherapeutics Inc Corp (BOLT) exhibits a P/S ratio of 4.18, which is 368.50% above the industry average. Given its robust revenue growth of 90.10%, this premium appears sustainable.
What is the current P/B ratio for Bolt Biotherapeutics Inc (BOLT) as of Jan 09 2026?
As of Jan 09 2026, Bolt Biotherapeutics Inc (BOLT) has a P/B ratio of 0.35. This indicates that the market values BOLT at 0.35 times its book value.
What is the current FCF Yield for Bolt Biotherapeutics Inc (BOLT) as of Jan 09 2026?
As of Jan 09 2026, Bolt Biotherapeutics Inc (BOLT) has a FCF Yield of -424.67%. This means that for every dollar of Bolt Biotherapeutics Inc’s market capitalization, the company generates -424.67 cents in free cash flow.
What is the current Forward P/E ratio for Bolt Biotherapeutics Inc (BOLT) as of Jan 09 2026?
As of Jan 09 2026, Bolt Biotherapeutics Inc (BOLT) has a Forward P/E ratio of -0.37. This means the market is willing to pay $-0.37 for every dollar of Bolt Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bolt Biotherapeutics Inc (BOLT) as of Jan 09 2026?
As of Jan 09 2026, Bolt Biotherapeutics Inc (BOLT) has a Forward P/S ratio of 4.18. This means the market is valuing BOLT at $4.18 for every dollar of expected revenue over the next 12 months.